Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) FCF Margin (2017 - 2025)

Historic FCF Margin for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to 78028.67%.

  • Crinetics Pharmaceuticals' FCF Margin changed N/A to 78028.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 23061.95%, marking a year-over-year decrease of 32748500.0%. This contributed to the annual value of 22118.77% for FY2024, which is 178577400.0% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported FCF Margin of 78028.67% as of Q3 2025.
  • Crinetics Pharmaceuticals' 5-year FCF Margin high stood at 435.32% for Q1 2022, and its period low was 78028.67% during Q3 2025.
  • Its 5-year average for FCF Margin is 13378.34%, with a median of 8466.88% in 2024.
  • The largest annual percentage gain for Crinetics Pharmaceuticals' FCF Margin in the last 5 years was 35426600bps (2025), contrasted with its biggest fall of -163782800bps (2025).
  • Over the past 5 years, Crinetics Pharmaceuticals' FCF Margin (Quarter) stood at 2125.88% in 2021, then crashed by -135bps to 5004.37% in 2022, then plummeted by -159bps to 12959.25% in 2023, then increased by 6bps to 12180.2% in 2024, then tumbled by -541bps to 78028.67% in 2025.
  • Its last three reported values are 78028.67% in Q3 2025, 8637.54% for Q2 2025, and 24845.15% during Q1 2025.